{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T10:44:39Z","timestamp":1788864279531,"version":"build-2803163510"},"reference-count":37,"publisher":"The Endocrine Society","issue":"4","license":[{"start":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T00:00:00Z","timestamp":1765324800000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Ascendis Pharma Bone Diseases A\/S","award":["NCT04009291"],"award-info":[{"award-number":["NCT04009291"]}]},{"name":"Ascendis Pharma Bone Diseases A\/S","award":["2018-004815-33"],"award-info":[{"award-number":["2018-004815-33"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Context<\/jats:title>\n                    <jats:p>Individuals with hypoparathyroidism experience a range of physical and cognitive symptoms and reduced quality of life (QoL) despite management with conventional therapy (active vitamin D and calcium).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This analysis investigated the long-term impact of parathyroid hormone (PTH) replacement therapy with palopegteriparatide (YORVIPATH\u00ae) on symptoms, daily functioning, and well-being in adults with chronic hypoparathyroidism. Associations between patient characteristics and changes in patient-reported outcomes (PROs) were also analyzed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>PaTH Forward was a phase 2 clinical trial of palopegteriparatide with a 4-week randomized, double-blind, placebo-controlled period followed by an open-label extension period lasting through trial week 266. PRO measures were collected at baseline, weeks 4, 12, 26, 58, and annually thereafter through the end of the trial. The Hypoparathyroidism Patient Experience Scales (HPES) assess disease-specific symptoms and impacts on functioning and well-being. The Short Form Health Survey (SF-36v2) measures general health-related QoL. Data were analyzed using descriptive statistics and Mixed Models for Repeated Measures.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Palopegteriparatide treatment demonstrated significant improvements from baseline in disease-specific symptoms and impacts on daily functioning and well-being at week 12, which were sustained through week 110. Mean changes in PROs met thresholds for clinically meaningful within-patient improvement. Significant improvements in general health-related QoL were also shown in SF-36v2 scores. Results were generally similar across demographics and patient characteristics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Through week 110 of the PaTH Forward trial, PTH replacement therapy with palopegteriparatide was associated with significant improvements in disease-specific symptoms and impacts on daily functioning and well-being, as well as general health-related QoL.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1210\/clinem\/dgaf653","type":"journal-article","created":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T12:53:42Z","timestamp":1765025622000},"page":"945-952","source":"Crossref","is-referenced-by-count":3,"title":["Patient-reported outcomes in palopegteriparatide-treated adults with hypoparathyroidism: PaTH Forward trial extension"],"prefix":"10.1210","volume":"111","author":[{"given":"Mishaela","family":"Rubin","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Columbia University , New York, NY 10032 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1143-4926","authenticated-orcid":false,"given":"Andrea","family":"Palermo","sequence":"additional","affiliation":[{"name":"Research Unit of Metabolic Bone and Thyroid Disorders, Department of Medicine and Surgery, Universit\u00e0 Campus Bio-Medico di Roma , 00128 Rome ,","place":["Italy"]},{"name":"Unit of Metabolic Bone and Thyroid Disorders, Fondazione Policlinico Universitario Campus Bio-Medico , 00128 Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara","family":"Vokes","sequence":"additional","affiliation":[{"name":"Department of Medicine - Endocrinology, The University of Chicago , Chicago, IL 60637 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aliya A","family":"Khan","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine, McMaster University , Hamilton, ON L8S 4L8 ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Schwarz","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Rigshospitalet and University of Copenhagen , 2100 Copenhagen ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filomena","family":"Cetani","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, Endocrine Unit, University of Pisa , 56124 Pisa ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4182-3110","authenticated-orcid":false,"given":"Uberto","family":"Pagotto","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Diabetes Prevention and Care, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna , 40100 Bologna BO ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Tsourdi","sequence":"additional","affiliation":[{"name":"Department of Medicine III and Center for Healthy Aging, Technische Universit\u00e4t Dresden , 01069 Dresden ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanja","family":"Sikjaer","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Internal Medicine, Aarhus University Hospital , 8200 Aarhus N ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn M","family":"Pfeiffer","sequence":"additional","affiliation":[{"name":"The Brod Group , Mill Valley, CA 94941 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meryl","family":"Brod","sequence":"additional","affiliation":[{"name":"The Brod Group , Mill Valley, CA 94941 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori D","family":"McLeod","sequence":"additional","affiliation":[{"name":"RTI Health Solutions , Research Triangle Park, NC 27709 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Zhao","sequence":"additional","affiliation":[{"name":"Endocrine and Rare Disease Medical Sciences, Ascendis Pharma, Inc , Palo Alto, CA 94304 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wahidullah","family":"Noori","sequence":"additional","affiliation":[{"name":"Endocrine and Rare Disease Medical Sciences, Ascendis Pharma, Inc , Palo Alto, CA 94304 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimee D","family":"Shu","sequence":"additional","affiliation":[{"name":"Endocrine and Rare Disease Medical Sciences, Ascendis Pharma, Inc , Palo Alto, CA 94304 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1582-534X","authenticated-orcid":false,"given":"Alden R","family":"Smith","sequence":"additional","affiliation":[{"name":"Endocrine and Rare Disease Medical Sciences, Ascendis Pharma, Inc , Palo Alto, CA 94304 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2025,12,9]]},"reference":[{"issue":"6","key":"2026031619582106000_dgaf653-B1","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1210\/jc.2015-3909","article-title":"Presentation of hypoparathyroidism: etiologies and clinical features","volume":"101","author":"Shoback","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2026031619582106000_dgaf653-B2","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1210\/clinem\/dgae800","article-title":"Cognitive function in individuals with chronic hypoparathyroidism\u2014a prospective observational study","volume":"110","author":"Tmava-Berisha","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"2026031619582106000_dgaf653-B3","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1093\/jbmr\/zjae063","article-title":"Hypoparathyroidism: changes in brain structure, cognitive impairment, and reduced quality of life","volume":"39","author":"Sikjaer","year":"2024","journal-title":"J Bone Miner Res"},{"issue":"6","key":"2026031619582106000_dgaf653-B4","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1210\/jc.2015-3907","article-title":"Management of hypoparathyroidism: summary statement and guidelines","volume":"101","author":"Brandi","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2026031619582106000_dgaf653-B5","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/cen.14128","article-title":"Burden of illness in not adequately controlled chronic hypoparathyroidism: findings from a 13-country patient and caregiver survey","volume":"92","author":"Siggelkow","year":"2020","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"6","key":"2026031619582106000_dgaf653-B6","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1210\/jc.2015-3908","article-title":"Epidemiology and diagnosis of hypoparathyroidism","volume":"101","author":"Clarke","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2026031619582106000_dgaf653-B7","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1002\/jbmr.2273","article-title":"Postsurgical hypoparathyroidism\u2013risk of fractures, psychiatric diseases, cancer, cataract, and infections","volume":"29","author":"Underbjerg","year":"2014","journal-title":"J Bone Miner Res"},{"issue":"9","key":"2026031619582106000_dgaf653-B8","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1002\/jbmr.2501","article-title":"The epidemiology of nonsurgical hypoparathyroidism in Denmark: a nationwide case finding study","volume":"30","author":"Underbjerg","year":"2015","journal-title":"J Bone Miner Res"},{"issue":"10","key":"2026031619582106000_dgaf653-B9","doi-asserted-by":"crossref","first-page":"4866","DOI":"10.1007\/s12325-025-03264-x","article-title":"Risk of cardiovascular events, infections, and renal complications in postsurgical chronic hypoparathyroidism: a US Medicare claims retrospective analysis","volume":"42","author":"Noori","year":"2025","journal-title":"Adv Ther"},{"issue":"3","key":"2026031619582106000_dgaf653-B10","doi-asserted-by":"crossref","first-page":"P1","DOI":"10.1530\/EJE-18-0609","article-title":"Standards of care for hypoparathyroidism in adults: a Canadian and International Consensus","volume":"180","author":"Khan","year":"2019","journal-title":"Eur J Endocrinol"},{"issue":"7","key":"2026031619582106000_dgaf653-B11","doi-asserted-by":"crossref","first-page":"671","DOI":"10.4158\/EP13328.OR","article-title":"Understanding the burden of illness associated with hypoparathyroidism reported among patients in the PARADOX study","volume":"20","author":"Hadker","year":"2014","journal-title":"Endocr Pract"},{"issue":"3","key":"2026031619582106000_dgaf653-B12","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/cen.14701","article-title":"What are predictors of impaired quality of life in patients with hypoparathyroidism?","volume":"97","author":"Buttner","year":"2022","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"6","key":"2026031619582106000_dgaf653-B13","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1111\/cen.13593","article-title":"Health-related quality of life in patients with nonsurgical hypoparathyroidism and pseudohypoparathyroidism","volume":"88","author":"Underbjerg","year":"2018","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"2","key":"2026031619582106000_dgaf653-B14","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1530\/eje.0.1460215","article-title":"Well-being, mood and calcium homeostasis in patients with hypoparathyroidism receiving standard treatment with calcium and vitamin D","volume":"146","author":"Arlt","year":"2002","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"2026031619582106000_dgaf653-B15","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s12020-023-03443-2","article-title":"Impairments in quality of life and predictors of symptom burden in patients with hypoparathyroidism: results from a population-based survey","volume":"82","author":"Buttner","year":"2023","journal-title":"Endocrine"},{"issue":"12","key":"2026031619582106000_dgaf653-B16","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.1002\/jbmr.4691","article-title":"Evaluation and management of hypoparathyroidism summary statement and guidelines from the second international workshop","volume":"37","author":"Khan","year":"2022","journal-title":"J Bone Miner Res"},{"issue":"8","key":"2026031619582106000_dgaf653-B17","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1002\/jbmr.4016","article-title":"A randomized double-blind placebo-controlled first-in-human phase 1 trial of TransCon PTH in healthy adults","volume":"35","author":"Karpf","year":"2020","journal-title":"J Bone Miner Res"},{"issue":"11","key":"2026031619582106000_dgaf653-B18","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1002\/jbmr.3824","article-title":"Design and preclinical development of TransCon PTH, an investigational sustained-release PTH replacement therapy for hypoparathyroidism","volume":"34","author":"Holten-Andersen","year":"2019","journal-title":"J Bone Miner Res"},{"key":"2026031619582106000_dgaf653-B19"},{"key":"2026031619582106000_dgaf653-B20"},{"key":"2026031619582106000_dgaf653-B21"},{"key":"2026031619582106000_dgaf653-B22"},{"issue":"1","key":"2026031619582106000_dgaf653-B23","doi-asserted-by":"crossref","first-page":"e372","DOI":"10.1210\/clinem\/dgab577","article-title":"PaTH forward: a randomized, double-blind, placebo-controlled phase 2 trial of TransCon PTH in adult hypoparathyroidism","volume":"107","author":"Khan","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2026031619582106000_dgaf653-B24","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/jbmr.4726","article-title":"Efficacy and safety of parathyroid hormone replacement with TransCon PTH in hypoparathyroidism: 26-week results from the phase 3 PaTHway trial","volume":"38","author":"Khan","year":"2023","journal-title":"J Bone Miner Res"},{"issue":"4","key":"2026031619582106000_dgaf653-B25","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1210\/clinem\/dgae693","article-title":"Efficacy and safety of TransCon PTH in adults with hypoparathyroidism: 52-week results from the phase 3 PaTHway trial","volume":"110","author":"Clarke","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"2026031619582106000_dgaf653-B26","volume-title":"User's Manual for the SF-36v2 Health Survey","author":"Maruish","year":"2011","edition":"3rd ed"},{"issue":"2","key":"2026031619582106000_dgaf653-B27","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s40271-019-00388-5","article-title":"Assessing the patient experience of hypoparathyroidism symptoms: development of the hypoparathyroidism patient experience scale-symptom (HPES-symptom)","volume":"13","author":"Brod","year":"2020","journal-title":"Patient"},{"issue":"1","key":"2026031619582106000_dgaf653-B28","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s11136-020-02607-1","article-title":"Living with hypoparathyroidism: development of the hypoparathyroidism patient experience scale-impact (HPES-impact)","volume":"30","author":"Brod","year":"2021","journal-title":"Qual Life Res"},{"issue":"1","key":"2026031619582106000_dgaf653-B29","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s41687-021-00320-2","article-title":"Psychometric validation of the hypoparathyroidism patient experience scales (HPES)","volume":"5","author":"Brod","year":"2021","journal-title":"J Patient Rep Outcomes"},{"key":"2026031619582106000_dgaf653-B30","unstructured":"Rubin M, Palermo A, Vokes T, et al \u00a0JCEM Rubin et al Supplemental Material 2025. Figshare. 2025. doi:10.6084\/m9.figshare.30888056.v1"},{"issue":"1","key":"2026031619582106000_dgaf653-B31","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/S0895-4356(02)00537-1","article-title":"Comparative responsiveness of generic and specific quality-of-life instruments","volume":"56","author":"Wiebe","year":"2003","journal-title":"J Clin Epidemiol"},{"issue":"6","key":"2026031619582106000_dgaf653-B32","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1210\/jc.2013-1239","article-title":"The effect of PTH(1-84) on quality of life in hypoparathyroidism","volume":"98","author":"Cusano","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"2026031619582106000_dgaf653-B33","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1002\/jbmr.4566","article-title":"Safety and efficacy of PTH 1-34 and 1-84 therapy in chronic hypoparathyroidism: a meta-analysis of prospective trials","volume":"37","author":"Puliani","year":"2022","journal-title":"J Bone Miner Res"},{"issue":"5","key":"2026031619582106000_dgaf653-B34","doi-asserted-by":"crossref","first-page":"714","DOI":"10.3390\/jpm13050714","article-title":"Parathyroid hormone (PTH)-related peptides family: an intriguing role in the central nervous system","volume":"13","author":"Dettori","year":"2023","journal-title":"J Pers Med"},{"issue":"1","key":"2026031619582106000_dgaf653-B35","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.neuroscience.2009.04.054","article-title":"Parathyroid hormone 2 receptor and its endogenous ligand tuberoinfundibular peptide of 39 residues are concentrated in endocrine, viscerosensory and auditory brain regions in macaque and human","volume":"162","author":"Bag\u00f3","year":"2009","journal-title":"Neuroscience"},{"issue":"26","key":"2026031619582106000_dgaf653-B36","doi-asserted-by":"crossref","first-page":"15455","DOI":"10.1074\/jbc.270.26.15455","article-title":"Identification and functional expression of a receptor selectively recognizing parathyroid hormone, the PTH2 receptor","volume":"270","author":"Usdin","year":"1995","journal-title":"J Biol Chem"},{"issue":"2","key":"2026031619582106000_dgaf653-B37","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1002\/hec.1134","article-title":"True health vs response styles: exploring cross-country differences in self-reported health","volume":"16","author":"Jurges","year":"2007","journal-title":"Health Econ"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgaf653\/65823685\/dgaf653.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/111\/4\/945\/65823685\/dgaf653.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/111\/4\/945\/65823685\/dgaf653.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T23:58:46Z","timestamp":1773705526000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/111\/4\/945\/8375704"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,9]]},"references-count":37,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,12,9]]},"published-print":{"date-parts":[[2026,3,17]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgaf653","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,4]]},"published":{"date-parts":[[2025,12,9]]}}}